Alnylam Pharmaceuticals, Inc.
ALNYNasdaqCIK 1178670HealthcareFiscal year ends Dec 31
Reports and events: 310 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2908:20 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001178670-26-000076 |
| 2026-10-2908:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001178670-26-000074 |
| 2026-07-3008:11 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001178670-26-000062 |
| 2026-07-3008:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001178670-26-000060 |
| 2026-05-2716:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001628280-26-038499 |
| 2026-04-3008:16 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-028605 |
| 2026-04-3008:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-028601 |
| 2026-04-0616:30 ET | DEF 14A | Proxy statementPeriod 2026-05-20 | 0001628280-26-023923 |
| 2026-03-0417:17 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-26-014728 |
| 2026-02-1208:12 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-007497 |
| 2026-02-1208:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-007491 |
| 2026-01-1207:30 ET | 8-K | 2.02 Results of operations | 0001628280-26-001755 |
| 2025-12-1107:25 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-315047 |
| 2025-12-0316:49 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-25-055084 |
| 2025-10-3008:16 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001628280-25-047345 |
| 2025-10-3008:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-047342 |
| 2025-10-0316:15 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-230201 |
| 2025-09-1217:17 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-202366 |
| 2025-09-1007:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-199686 |
| 2025-07-3108:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001178670-25-000090 |
| 2025-07-3108:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001178670-25-000089 |
| 2025-06-1816:48 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001178670-25-000076 |
| 2025-05-1317:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results | 0001178670-25-000062 |
| 2025-05-0108:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001178670-25-000052 |
| 2025-05-0108:09 ET | 8-K | 9.01 Financial statements and exhibits | 0001178670-25-000050 |
| 2025-03-2416:40 ET | DEF 14A | Proxy statementPeriod 2025-05-08 | 0001178670-25-000040 |
| 2025-03-2118:13 ET | 8-K | 8.01 Other events | 0001178670-25-000038 |
| 2025-03-0516:33 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001178670-25-000031 |
| 2025-02-1308:31 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001178670-25-000026 |
| 2025-02-1308:09 ET | 8-K | 9.01 Financial statements and exhibits | 0001178670-25-000020 |
| 2025-01-1307:31 ET | 8-K | 2.02 Results of operations | 0001178670-25-000008 |
| 2024-10-3108:22 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001178670-24-000053 |
| 2024-10-3108:10 ET | 8-K | 9.01 Financial statements and exhibits | 0001178670-24-000052 |
| 2024-08-0108:22 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001178670-24-000041 |
| 2024-08-0108:11 ET | 8-K | 9.01 Financial statements and exhibits | 0001178670-24-000039 |
| 2024-05-2016:34 ET | 8-K | 5.07 Shareholder vote results | 0001178670-24-000027 |
| 2024-05-0208:21 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001178670-24-000023 |
| 2024-05-0208:11 ET | 8-K | 9.01 Financial statements and exhibits | 0001178670-24-000021 |
| 2024-04-0116:31 ET | DEF 14A | Proxy statementPeriod 2024-05-16 | 0001193125-24-083454 |
| 2024-03-0416:33 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-057906 |
| 2024-02-1516:23 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001178670-24-000008 |
| 2024-02-1508:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001157523-24-000253 |
| 2024-01-1916:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-011278 |
| 2024-01-0807:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-003854 |
| 2023-11-0208:22 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001178670-23-000023 |
| 2023-11-0208:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001157523-23-001622 |
| 2023-10-1007:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-253084 |
| 2023-09-2817:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-245768 |
| 2023-08-0308:18 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001178670-23-000015 |
| 2023-08-0308:10 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-23-202313 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 31, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.